Literature summary for 2.4.1.B62 extracted from

Baliban, S.M.; Michael, A.; Shammassian, B.; Mudakha, S.; Khan, A.S.; Cocklin, S.; Zentner, I.; Latimer, B.P.; Bouillaut, L.; Hunter, M.; Marx, P.; Sardesai, N.Y.; Welles, S.L.; Jacobson, J.M.; Weiner, D.B.; Kutzler, M.A.
An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo (2014), Infect. Immun., 82, 4080-4091.

Application

Application	Comment	Organism
medicine	construction of highly optimized plasmids encoding the receptor-binding domains from TcdA and TcdB in which any putative N-linked glycosylation sites are altered to test the potential of DNA vaccination against Clostridium difficile-associated disease. In mice and nonhuman primates, vaccination induces significant levels of both anti-receptor-binding domain antibodies (blood and stool) and receptor-binding domain-specific antibody-secreting cells. Sera from immunized mice and nonhuman primates can detect receptor-binding domain protein from transfected cells, as well as neutralize purified toxins in an in vitro cytotoxicity assay. Mice that are immunized with plasmids or given nonhuman-primate sera are protected from a lethal challenge with purified TcdA and/or TcdB. Immunized mice are significantly protected when challenged with Clostridium difficile spores from homologous (VPI 10463) and heterologous, epidemic (UK1) strains	Clostridioides difficile

Organism	UniProt	Comment	Textmining
Clostridioides difficile	P16154	-	-
Clostridioides difficile	P18177	-	-